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Abstract
Plumbagin(PL), a herbal compound derived from roots of the medicinal plant Plumbago zeylanica, has been shown to have
immunosuppressive properties. Present report describes that PL is a potent novel agent in control of encephalitogenic T cell
responses and amelioration of mouse experimental autoimmune encephalomyelitis (EAE), through down-regulation of JAK-
STAT pathway. PL was found to selectively inhibit IFN-c and IL-17 production by CD4
+ T cells, which was mediated through
abrogated phosphorylation of JAK1 and JAK2. Consistent with IFN-c and IL-17 reduction was suppressed STAT1/STAT4/T-
bet pathway which is critical for Th1 differentiation, as well as STAT3/ROR pathway which is essential for Th17
differentiation. In addition, PL suppressed pro-inflammatory molecules such as iNOS, IFN-c and IL-6, accompanied by
inhibition of IkB degradation as well as NF-kB phosphorylation. These data give new insight into the novel immune
regulatory mechanism of PL and highlight the great value of this kind of herb compounds in probing the complex cytokine
signaling network and novel therapeutic targets for autoimmune diseases.
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Introduction
As a chronic human autoimmune disease, multiple sclerosis
(MS) is mainly initiated by inflammatory responses of T
lymphocytes reactive to myelin antigens in the central nervous
system (CNS), leading to inflammatory demyelination and
subsequent axonal injury [1,2]. The animal model, experimental
autoimmune encephalomyelitis (EAE), is widely used to unravel
the mechanisms of autoimmune inflammation in MS [3]. It is well
known that autoreactive T helper (Th) cells are involved in the
disease pathogenesis. Th1 cells (IFN-c producing CD4
+ T cells)
and Th17 cells (IL-17 producing CD4
+ T cells) play critical roles
in the effector stage of EAE, whereas Th2 cells and Th2-type
cytokines such as IL-4, IL-10 downregulate the disease [4]. EAE is
markedly suppressed in mice lacking IL-17 or IL-17 receptor, and
IL-17-specific inhibition attenuates inflammation [5–9]. Through
production of proinflammatory cytokines such as IL-6, IFN-c, IL-
17, Th1 and Th17 cells recruit other inflammatory cells into CNS
lesions, resulting in chronic inflammation and demyelination of
CNS [4,10].
It is understood that the JAK-STAT pathway is the major
signaling pathway regulating Th1 and Th17 differentiation and
their functions [11]. Among STATs which mainly activated
through phosphorylation by JAK1, JAK2 and TYK2, STAT1 and
STAT4 are involved in Th1 differentiation while STAT3 is
activated by IL-6 and IL-23 and mainly involved in Th17
differentiation [12,13]. These are mediated through key transcrip-
tion factors such as T-bet and RORct/RORa, each for Th1 and
Th17 specifically [14–16]. There are cross regulations between
STAT and NF-kB signaling pathways. Besides, as cytokines and
NF-kB signaling pathways are deeply related cascades that
involved in immune response and inflammation, NF-kB regulates
the expression of many proinflammatory cytokines such as IFN-c,
IL-6 [17].
In a recent study, the principal MS therapies in current clinical
use were extensively analyzed, including IFN-b and glatiramer
acetate [18]. However, these are only modestly effective, or have
certain safety concerns. In this regard, exploiting novel anti-
inflammatory compounds that can target multiple checkpoints or
mechanisms is certainly a priority.
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone, PL) is a
natural bicyclic naphthoquinone found in the plants of Droseraceae,
Plumbaginaceae, Ancistrocladaceae and Dioncophyllaceae families. It has
many potent biological activities, including antioxidant [19,20],
anti-inflammatory [21–24], anti-tumor [22,25], antibacterial and
antifungal activities [26,27]. PL exhibits its anti-tumor activity
mainly through suppressing NF-kB signal pathway [28]. As a
critical transcription factor, NF-kB also has its central role in
regulating leukocytes proliferation, expression of immunoregula-
tory genes and adaptive immune responses. It is found that PL
inhibited T cell proliferation in response to polyclonal mitogen
Concanavalin A (Con A) by blocking cell cycle progression and
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6 and IFN-c [21].
Based on above observations, we hypothesized that the
immunomodulatory effects of PL may be exploited for use in the
treatment of autoimmune disorders. In this study, we investigated
the potential regulatory properties of PL and its underlying
mechanism in mouse EAE. Results presented here provide new
insight into the novel regulatory mechanism of herbal compounds
such as PL in treatment of autoimmune diseases.
Materials and Methods
Mice
Female C57BL/6 (B6) mice were purchased from the Shanghai
Laboratory Animal Center, Chinese Academy of Sciences,
Shanghai. Mice were maintained under pathogen-free conditions.
Plumbagin (with purity greater than 97%) was purchased from
Sigma-Aldrich. A 100 mM solution of plumbagin was prepared in
DMSO, stored at 220uC.
Induction and treatment of EAE
For EAE induction, B6 mice (10–12 wk) were immunized s.c.
with 300 mg of myelin oligodendrocyte glycoprotein (MOG
residues 35–55). Sequence of the peptide was Met-Glu-Val-Gly-
Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg- Asn-
Gly-Lys and displayed a purity of .95% (GL Biochem).
Immunization was performed by mixing MOG peptide in
Complete Freund’s Adjuvant containing 5 mg/ml heat-killed
H37Ra, strain of Mycobacterium tuberculosis (Difco Laborato-
ries). 400 ng Pertussis toxin (List Biological Laboratories) in PBS-
50 mM NaCl was administered i.p. on the day of immunization
and 24 h later. For treatment of EAE, PL was administered at
2 mg/kg or DMSO (Sigma-Aldrich) as vehicle control i.p. daily
from day 7 postimmunization onwards. The prevention protocol
differed from the treatment protocol only at the start of PL
administration (3 days before immunization). Mice were weighed
and examined daily for disease symptoms, assessed using the
standard score system: 0, No obvious changes in motor functions;
1.0, Limp tail; 2.0, Limp tail and wobbly gait; 3.0, Bilateral hind
limb paralysis; 4.0, Complete hind limb and partial fore limb
paralysis; 5.0 Death. Animal procedures were approved by the
institutional Animal Ethics Committee of East China Normal
University.
Histopathology
After intracardiac fixative perfusion, spinal cords were isolated
from mice, transcardially perfused with 4% paraformaldehyde for
overnight. Tissues were treated in ethanol and xylene as usual and
paraffin-embedded 5 mm sections were stained with H&E or Luxol
fast blue. For immunohistochemisty staining of CD4
+ T cells,
spinal cords were removed from mice, perfused with PBS, and
incubated in 30% sucrose at 4uC overnight. Frozen specimens
were sectioned at 5 mm with a cryostat. The frozen slices were
developed with Histostain-Plus Kit (MR Biotech), according to the
manufacturer’s instructions.
MOG-specific T cell proliferation assay
For in vitro proliferation, splenocytes were isolated from EAE
mice and cultivated in triplicates in complete RPMI1640 medium
(GIBCO22400, with 10% FBS) at 2610
5 per well in 96-well plates
in presence or absence of the MOG peptide (20 mg/ml). PL was
added in vitro at the indicated concentrations and all cultures were
maintained at 37uCi n5 %C O 2 for 48 h. T cell proliferation was
measured using a MTS kit (CellTiter 96H AQueous One Solution
Cell Proliferation Assay, Promega), according to the manufactur-
er’s instructions. For ex vivo assay, splenocytes were isolated 18 days
postimmunization from DMSO vehicle-treated and PL-treated
mice, and examined for proliferation in the presence or absence of
MOG peptide.
RT-PCR and quantitative real-time PCR analysis
Total RNA was extracted from splenocytes using TRIzol
(Invitrogen). First-strand cDNA was synthesized using Prime-
ScriptTM RT reagent kit (Takara), according to the manufactur-
er’s instructions. mRNA expression was determined by RT-PCR
or quantitative real-time PCR. RT-PCR products were analyzed
on a 1.5% multiwelled agarose gel. Electrophoresis was carried out
in 16TAE buffer at 100 V for 30 minutes. Real-time PCR was
performed using SYBR Green Master Mix under standard
thermocycler conditions. Data were collected and quantitatively
analyzed on a Mx3005p quantitative PCR system (Stratagene).
Results were presented as fold increases relative to the expression
of house keeping b-actin. Sequences of PCR primers were listed in
Table 1.
Measurement of cytokine production
At 18 days after MOG immunization, splenocytes at 2610
6 /ml
isolated from PL-treated or vehicle-treated mice were stimulated
with the MOG peptide (20 mg/ml) in complete RPMI 1640
medium. Supernatants were harvested after 48 h and assays for
IFN-c and IL-17 were performed in triplicates by ELISA using
commercial kits (Dakewe Systems) according to the manufacturer’s
recommendations.
Table 1. Specific primers used in PCR analysis.
Molecule Primer Sequence
b-actin Forward 59-GCTGTCCCTGTATGCCTCT-39
Reverse 59-GTCACGCACGATTTCCCTC-39
IL-13 Forward 59-GCTTATTGAGGAGCTGAG-39
Reverse 59-GGGCTACTTCGATTTTGG-39
IL-4 Forward 59-TTTGAACGAGGTCACAGG-39
Reverse 59-GCATGATGCTCTTTAGGC-39
IL-6 Forward 59-TTCTTGGGACTGATGCTG-39
Reverse 59-CTGGCTTTGTCTTTCTTGTT-39
IL-17a Forward 59-CTCAACCGTTCCACGTCAC-39
Reverse 59-ACACCCACCAGCATCTTCT-39
IFN-c Forward 59-TCTGAGACAATGAACGCTAC-39
Reverse 59-TGGACCACTCGGATGAG-39
iNOS Forward 59-GGACGAGACGGATAGGCA-39
Reverse 59-CATCTCGGGTGCGGTAG-39
RORa Forward 59-CGCTCGTGGCTTCAGGAAAAGGT-39
Reverse 59-AGAAGTGCTCGGGCGCGACAT-39
RORct Forward 59-CATCTCTGCAAGACTCATCG-39
Reverse 59-CAGGGGATTCAACATCAGTG-39
TNFa Forward 59-TCCCTTTCACTCACTGGC-39
Reverse 59-ACTTGGTGGTTTGCTACG-39
Foxp3 Forward 59-AGGAGAAAGCGGATACC-39
Reverse 59-CAGGGAGGAGTTCAGTAGAG-39
doi:10.1371/journal.pone.0027006.t001
Amelioration of EAE by Plumbagin
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e27006Immunoblotting
Splenocytes isolated from PL-treated mice, vehicle-treated EAE
mice or control mice were cultured in complete RPMI 1640
medium at a density of 5610
6 /ml in the presence or absence of
the MOG peptide (20 mg/ml) for 24 h. CD4
+ T cells were purified
using magnetic microbeads (Dynal Mouse CD4 Negative Isolation
Kit, Invitrogen, purity .95%). Cells were directly lysed in SDS
sample buffer. Proteins were loaded onto a 8% SDS-polyacryl-
amide gel and subjected to electrophoresis. The separated proteins
were electro-transferred onto a nitrocellulose membrane (Schlei-
cher & Schuell MicroScience) using a Mini Trans-Blot apparatus
(Bio-Rad). The membrane was then blocked with skimmed milk
and probed with specific antibodies (Cell Signaling Technology)
followed by data analysis on a Odyssey infrared imaging system
(LI-COR).
Statistics
Student’s t test was used to analyze the differences between
different groups. Data were presented as mean 6 standard
deviation (SD). Difference between values was considered
statistically significant when p,0.05.
Results
Amelioration of EAE by PL treatment
Splenocytes were isolated from EAE mice and subjected to in
vitro MOG stimulation. PL, with a structure of 1,4-naphthoqui-
none (Fig. 1A) was added to test its effect on MOG specific T
cell reactivity. It was found that PL significantly inhibit
proliferation of MOG-reactiveTc e l l si nad o s e - d e p e n d e n t
m a n n e r( F i g .1 C ) .I na d d i t i o n ,P La lso significantly inhibited
MOG specific T cell reactivity in an ex vivo system using
splenocytes from vehicle-treated and PL-treated EAE mice
stimulated by MOG (Fig. 1B). PL had a low IC50 at 1 mM.
Under this concentration, it displayed minimum cytotoxicity
(data not shown).
As illustrated in Fig. 2, no matter PL was administered at 7
days post immunization, or 3 days before immunization, it
resulted in a significant reduction in EAE score as compared with
the vehicle control. The observed clinical effect of PL accom-
panied by a marked decrease of inflammation and demyelination
in histological analysis of affected spinal cord. Furthermore,
this observation was consistent with the immunohistochemical
result which showed a decreased infiltration of CD4
+ Tc e l l si n
affected spinal cord of PL-treated mice (Fig. 3). It is evident that
the therapeutic effect of PL was associated with a marked
reduction in the number of CNS infiltrating encephalitogenic
CD4
+ T cells.
PL inhibited proinflammatory molecule expression in
MOG-reactive T cells
The significant treatment effect of PL in EAE prompted us to
investigate in detail about its potential regulatory mechanisms
and to identify the target molecules through which PL might
regulate the immune system. To this end, splenocytes were
isolated from PL-treated and vehicle-treated EAE mice and
characterized for T cell cytokine profile in response to in vitro
challenge by the disease-eliciting MOG peptide. MOG-reactive
T cells derived from PL-treated mice displayed a markedly
altered cytokine profile from that of vehicle-treated mice,
characterized by significantly reduced production of proinflam-
matory cytokines including IFN-c and IL-17 (Fig. 4A). In
addition, the effect of PL on mRNA expression of proinflamma-
tory cytokines and other molecules was studied using splenocytes
isolated from EAE mice or PL-treated mice and cultured in the
presence or absence of the MOG peptide and PL at 37uCi n5 %
CO2 for 24 h. The mRNA expression of IL-17, IFN-c,I L - 6 ,
TNF-a and iNOS were decreased, as well as RORct expression,
which is critically involved in Th17 differentiation. At the same
time, it seems that Th2 type cytokines such as IL-5, IL-13 were
up-regulated by PL. The mRNA expression of Foxp3, an
important transcription factor for Treg cells, was also increased
by PL treatment (Fig. 4, B and C).
The effect of PL on CD4
+ T cell differentiation was
mediated through the JAK/STAT signaling pathway
Because the JAK/STAT signaling pathway is known to play a
critical role in differentiation and survival of Th1 and Th17
lineages, we investigated the expression or phosphorylation level of
transcription factors involved in the development of Th1 (STAT1,
STAT4 and T-bet ) and Th17 (STAT3, RORct and RORa).
Splenocytes from PL-treated mice, EAE mice or control mice were
cultured in the presence of MOG peptide for 24 h. CD4
+ T cells
were purified using magnetic microbeads and subjected to analysis
of key signaling molecules of the JAK/STAT pathway. Immuno-
blotting demonstrated that phosphorylation of JAK/STAT
pathway was stimulated by EAE induction (Fig. S1), whereas PL
treatment significantly inhibited phosphorylation of STAT1,
STAT4 (Fig. 5A) and STAT3 (Fig. 5B) as well as the upstream
kinases JAK1, JAK2 (Fig. 5C). The expression of key transcription
factors T-bet and RORct/RORa critically required for Th1 and
Th17 differentiation respectively were also markedly inhibited in
CD4
+ T cells derived from PL-treated mice (Fig. 5, A and B).
These data provide strong evidence that PL directly inhibited Th1,
Th17 differentiation and function.
Figure 1. Proliferation of MOG-reactive T cells was significantly
inhibited by Plumbagin. A, Chemical structure of Plumbagin. B,
Splenocytes were isolated 18 days postimmunization from vehicle-
treated and PL-treated EAE mice, and examined ex vivo for proliferation
by MTS in the presence (MOG) or absence (Med) of MOG peptide. C,
Proliferation as measured by MTS in splenocytes from EAE mice
stimulated in vitro by MOG peptide with or without PL. Data are
presented as mean 6 SD of triplicates. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0027006.g001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e27006Figure 2. Amelioration of EAE by PL treatment. A&B, Clinical scores of EAE in mice. PL (2 mg/kg) or vehicle control was administered i.p. daily in
EAE mice, started from day 7 postimmunization (A) or day3 before immunization (B). Data are expressed as mean 6 SD and represent three
independent experiments.
doi:10.1371/journal.pone.0027006.g002
Figure 3. Histology and immunohistochemical staining of spinal cord tissue. Spinal cord sections obtained from normal control mice, EAE
mice or PL-treated mice at day 18 postimmunization (treatment protocol) were analyzed by Luxol Fast Blue staining for demyelination, H&E staining
for inflammation, and Immunohistochemical staining (IH) for CD4
+ T cell infiltration. 625 or 6400. Data presented are representative of three
independent experiments. CD4
+ T cell infiltrates stained by immunohistochemistry were enumerated microscopically in normal mice (10.3363.51),
EAE mice (128.6767.02) and PL-treated mice (34.3363.51), respectively. Data are expressed as mean 6 SD. p,0.001 for EAE mice versus normal mice,
p,0.01 for PL-treated mice versus EAE mice.
doi:10.1371/journal.pone.0027006.g003
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was correlated with the downregulation of NF-kB
signaling
PL has been shown to suppress the constitutive NF-kB
activation in lymphocytes, and the suppression of NF-kBb y
plumbagin resulted in inhibition of mitogen-induced activation
and proliferation of lymphocytes. As we observed the decreased
production of proinflammatory molecules such as iNOS, IL-6 and
IFN-c by PL-treated mice (Fig. 4), we proceed to investigate PL’s
regulatory effects on NF-kB signal pathway in CD4
+ T cells. As
expected, the result revealed that IkBa phosphorylation as well as
its degradation was suppressed by plumbagin. In the meantime,
the phosphorylation of p65 subunit of NF-kB was also inhibited
(Fig. 6).
Discussion
In inflammatory diseases and autoimmune diseases, CD4
+ T
cells serve as an important source of proinflammatory cytokines.
Depending on the environmental signals presented during
activation, naive CD4
+ T cells differentiate into distinct effector
lineages [29,30]. Among these are Th1 and Th17 lineages,
imprinted for IFN-c and IL-17 expression by upregulated
expression of T-bet and ROR, respectively. The combination
effect of IFN-c and IL-17 is essential in the effective induction and
maintenance of autoimmunity [4,31,32].
Although EAE has its drawbacks as a model for human MS, it is
still invaluable in investigating basic immunopathological mech-
anisms of MS, as well as providing a convenient animal model for
novel therapy testing and drug mechanism elucidation. Our study
presented here demonstrated that PL, a natural bicyclic naphtho-
quinone, exerts potent anti-inflammatory actions, resulting in
amelioration of EAE through unique signaling pathways. PL
inhibited MOG-specific lymphocyte proliferation which associates
with significant reduction of pro-inflammation cytokines as well as
CD4
+ T cells infiltration into spinal cord tissue. Both treatment
and prevention protocols showed that PL can markedly improve
the clinical symptom of EAE, but it did not significantly postpone
the disease onset. One of the possible explanation is that PL acts
directly upon encephalitogenic T cells.
As stated above, Th1 and Th17 cells are main pathogenic T
cells critically involved in the disease pathogenesis of MS and EAE
model [33], whereas JAK/STAT signaling pathway is one of the
major signaling networks that regulate T cell differentiation and
their activities [34]. In this study we demonstrated that PL affect
pathogenic Th1 and Th17 cells differentiation and functions
through regulation of JAK/STAT signaling pathway, resulting in
inhibition of pro-inflammatory cytokines such as IFNc and IL-17.
PL treatment inhibited both STAT1 and STAT4 phosphorylation
as well as the expression of T-bet in CD4
+ T cells, altering Th1
differentiation and the clinical course of EAE. It is understood that
phosphorylated STAT1 contributes to the transcription of T-bet
which bind to IFNc promoter, drive CD4
+ T cell differentiate
toward Th1 phenotype. Phosphorylated STAT4 also translocates
and binds to IFNc promoter, which initiate IFNc production and
contribute to the full differentiation of a Th1 cell [35]. On the
Figure 4. Cytokine and other molecule profiling of MOG-reactive T-cells in response to PL treatment. A, Splenocytes from PL-treated
mice (open bars) or EAE mice (solid bars) were challenged with MOG peptide, and culture supernatants were collected at 48 h for cytokine
measurement by ELISA. Data are presented as mean 6 SD (pg/ml). B, Splenocytes isolated from EAE mice were stimulated with MOG peptide in the
presence or absence of PL (0.5 mM) for 24 h. mRNA expression of selected genes was measured by RT-PCR. C, Splenocytes isolated from EAE mice and
PL-treated mice were stimulated with MOG peptide for 24 h. mRNA expression of stated genes was measured by real-time PCR.
doi:10.1371/journal.pone.0027006.g004
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+ T cells differentiation into Th17 cells is
mediated by TGF-b and IL-6 signaling via STAT3, RORct and
RORa transcription factors, which is further enhanced and
maintained by IL-23 and IL-21[36]. Our ex vivo analysis of CD4
+
T cells from mice immunized with MOG35–55 peptide indicated
that PL downregulates STAT3 phosphorylation and RORct/
RORa expression in CD4
+ T cells and decreased the encepha-
litogenic capacity of these cells. In addition, we found that PL
enhanced STAT5 phosphorylation,as well as expression of
FOXP3, the important transcription factor for Treg cells, which
means that PL might has a role in Treg differentiation. The
precise mechanism of the balance between Treg and Th17
differentiation induced by PL still needs to be elucidated [37].
It is worth noticing that NF-kB, a key mediator of inducible
transcription in the immune system and a hallmark of inflamma-
tory responses, traditionally focused on its role in the initiation of
innate and adaptive immune responses. STAT3 may directly or
indirectly interact with NF-kB, as reported previously [38,39].
Also, PL has been shown to suppress NF-kB activation and NF-kB
regulated gene transcription [28]. Consistent with these reports,
our results demonstrated that anti-inflammatory effects of PL are
likely to involve the NF-kB pathway. PL inhibits MOG induced
NF-kB activation in T cells by preventing phosphorylation and
degradation of IkBa. Apart from this, plumbagin also inhibited
phosphorylation of the p65 subunit of NF-kB. Together, these
resulted in the suppression of NF-kB regulated gene transcription
including certain proinflammatory cytokines and molecules (e.g.
INFc, IL6, iNOS).
In conclusion, PL exerted the novel anti-inflammatory proper-
ties in EAE and resulted in its amelioration. To our knowledge,
Figure 5. Inhibition of Th1 and Th17 cells by PL through suppressing JAK/STAT pathway. Splenocytes isolated from EAE mice or PL-
treated mice were re-stimulated with MOG peptide for 24 h. CD4
+ T-cells were purified and proteins subjected to electrophoresis and
immunoblotting. Membranes were probed with antibodies to JAK, STATs or their phosphorylated form, and other proteins as indicated. A, Molecules
related to Th1 differentiation; B, Molecules related to Th17 differentiation; C, JAK family.
doi:10.1371/journal.pone.0027006.g005
Figure 6. Inhibition of NF-kB signaling pathway by PL. CD4
+ T-
cells from PL-treated mice, EAE mice and adjuvant control mice were
cultured in the absence or presence of MOG peptide for 24 h, extracted
proteins were subjected to electrophoresis and analyzed by immuno-
blotting for phosphorylated and total p65 and IkBa.
doi:10.1371/journal.pone.0027006.g006
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differentiation and function, through JAK-STAT pathway. The
treatment effect of PL is achieved through targeting multiple
signaling molecules critically related to autoimmunity. It raises the
possibility that PL may be used as a potential treatment for
autoimmune diseases such as MS. In addition, this study provides
an example for using natural compounds in probing the complex
cytokine signaling network and novel therapeutic targets for
autoimmune diseases and other inflammatory conditions.
Supporting Information
Figure S1 Phosphorylation of JAK/STAT pathway stim-
ulated by MOG during EAE induction. Splenocytes isolated
from adjuvant control mice, EAE mice and PL-treated mice were
re-stimulated with MOG peptide for 24 h. CD4
+ T-cells were
purified and proteins subjected to electrophoresis and immuno-
blotting. Membranes were probed with antibodies to JAK, STATs
or their phosphorylated form. A, STATs, T-bet and ROR; B, JAK
family.
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